Examples of 'elotuzumab' in a sentence
Meaning of "elotuzumab"
elotuzumab (adjective): referring to a specific type of monoclonal antibody used in medical treatments, often related to cancer therapy. For example, 'The patient received elotuzumab treatment.'
Show more definitions
- A humanized monoclonal antibody.
How to use "elotuzumab" in a sentence
Basic
Advanced
elotuzumab
Empliciti contains the active substance elotuzumab.
The metabolic pathway of elotuzumab has not been characterized.
Elotuzumab is not expected to be excreted into human milk.
There is no human experience with elotuzumab during pregnancy.
Elotuzumab was labeled for use with lenalidomide and dexamethasone.
The active substance is elotuzumab.
Elotuzumab exhibits nonlinear pharmacokinetics with clearance of elotuzumab decreasing from.
Studies to evaluate the effect of elotuzumab on fertility have not been performed.
The following side effects have been reported in clinical trials with elotuzumab.
Elotuzumab is dosed via intravenous route and therefore is immediately and completely bioavailable.
The most serious adverse reaction that may occur during elotuzumab treatment is pneumonia.
Thus, the effect of elotuzumab on male and female fertility is unknown.
After reconstitution, each mL of concentrate contains 25 mg elotuzumab.
Elotuzumab will be given in combination with lenalidomide, which is contraindicated during pregnancy.
The pharmacokinetics ( PK ) of elotuzumab was studied in patients with multiple myeloma.
See also
Elotuzumab attaches to a target protein called SLAMF7.
Target-mediated clearance of elotuzumab increased with higher serum M-protein concentrations.
Elotuzumab only recognizes human SLAMF7 protein.
The recommended dose is 10 mg of elotuzumab per kilogram of your body weight.
Elotuzumab is produced in NS0 cells by recombinant DNA technology.
Infusion reactions have been reported in patients receiving elotuzumab see section 4.8.
In nonclinical models, elotuzumab has demonstrated synergistic activity when combined with lenalidomide or bortezomib.
Empliciti 300 mg powder for concentrate for solution for infusion elotuzumab.
Elotuzumab directly activates natural killer cells through both the SLAMF7 pathway and Fc receptors.
Empliciti 300 mg powder for concentrate elotuzumab.
Elotuzumab 10 mg / kg was administered intravenously each week for the first 2 cycles and every 2 weeks thereafter.
No dose adjustment is required for elotuzumab in patients over 65 years of age see section 5.2.
Elotuzumab attaches to the cells with the SLAMF7 protein, breaking them down.
In clinical studies, approximately 78 patients were evaluated with elotuzumab at 20 mg / kg without apparent toxic effects.
The total elotuzumab dose in mg the patient 's weight in kg x 10.
Infusion reaction Infusion reactions have been reported in patients receiving elotuzumab ( see section 4.8 ).
Elotuzumab has a dual mechanism-of-action.
Empliciti 300 mg powder for concentrate for solution for infusion Each vial contains 300 mg elotuzumab.
